SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS
The invention provides a chemical entity of Formula (I), wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and and their use in a wide range of methods, including metabolic and reaction kinetic studies, de...
Saved in:
Main Authors | , , , , , , , , |
---|---|
Format | Patent |
Language | English Spanish |
Published |
09.02.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention provides a chemical entity of Formula (I), wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive or motor impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non- human animal training protocols, and treating treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.
La invención proporciona una entidad química de la Fórmula (I), en donde R1, R2, R3, Y y n tienen cualquiera de los valores descritos en la presente y composiciones que comprenden estas entidades químicas; métodos para elaborarlos; y su uso en una amplia variedad de métodos, incluyendo estudios metabólicos y de reacción cinética, técnicas de detección y formación de imágenes, y tratamientos radioactivos; y terapias incluyendo la inhibición selectiva de MAO y MAO-B, mejora de plasticidad neuronal, tratamiento de trastornos neurológicos, provisión de neuroprotección, tratamiento de deterioro cognitivo o motriz asociado con un trastorno del CNS, mejora de la eficiencia del entrenamiento cognitivo y motriz, provisión de neurorecuperación y neuro-rehabilitación, mejora de la eficiencia de protocolos de entrenamiento humano-animal, y tratamiento de trastornos periféricos (incluyendo obesidad, diabetes, y trastornos cardiometábolicos) y sus co-morbilidades asociadas. |
---|---|
Bibliography: | Application Number: MX20150011144 |